Evoke Pharma (EVOK) investor relations material

Executive summary

• Net product sales for Q3 2025 were $4.3 million, a 61% year-over-year increase, driven by expanded pharmacy networks and higher refill rates.

• Entered into a definitive agreement to be acquired by QOL Medical for $11.00 per share in cash, with the transaction expected to close in Q4 2025.

• Cash and cash equivalents as of September 30, 2025, were $11.6 million, with ongoing concerns about the ability to continue as a going concern without additional funding or completion of the merger.

• Extended GIMOTI patent exclusivity through November 2038, enhancing long-term value.

Financial highlights

• Net product sales for the nine months ended September 30, 2025, were $11.1 million, up 60% year-over-year.

• Net loss for Q3 2025 was $1.16 million, or $(0.45) per share, improved from $1.31 million, or $(0.94) per share, in Q3 2024.

• Operating expenses for Q3 2025 were $5.4 million, up from $3.9 million year-over-year, mainly due to increased marketing and profit sharing.

• Cash used in operating activities for the nine months was $2.1 million, a significant improvement from $4.2 million in the prior year period.

• Cash and cash equivalents stood at $11.6 million as of September 30, 2025.

Outlook and guidance

• Existing cash and expected sales are projected to fund operations into Q4 2026, but this is contingent on the merger and continued sales growth.

• The acquisition by QOL Medical is anticipated to unlock further growth potential under new leadership.

• If the merger is not completed, additional funding will be required to continue as a going concern.